Friday, March 14, 2014

Harry Dent Predicts a Market Crash in the third quarter of 2014 & a Demographic Cliff in the developed world

Harry Dent of HS Dent Investment Management explains why he predicts a market crash in the third quarter of the year and that the U.S. is headed towards bankruptcy. Stock Market.. an aging Bull Market? Real Estate Party Over? Invest In Gold? Europe Crash Impact? The Government Has To Fail... Survive and Prosper in 2013 with Harry Dent. 
Please share this article

J.C. Penney (NYSE: JCP) is on the Verge of Signaling 'Buy'

Storied department store operator J.C. Penney (NYSE: JCP) made it back on my radar as the stock showed some notable relative strength (RS) during the past couple of weeks.
As is often the case when a troubled stock begins to show marginally more positive price movement, JCP's move has been accompanied by several positive news items.
On Feb. 19, Citigroup (NYSE: C) analyst Oliver Chen initiated coverage on JCP with a "neutral" rating and a $6.50 price target. At the time, shares were trading near $6.
After the close of trading on Feb. 26, the company reported its first quarterly profit in more than two years. Shares rallied in after-hours trading and closed up more than 25% the following day. This massive move was due in part to short covering, as many bearish traders were caught off guard.  (more)

Please share this article

Celldex Therapeutics, Inc. (NASDAQ: CLDX)

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. The company has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused precision targeted immunotherapy platform. Its lead drug candidates include rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma and a Phase II study for the treatment of recurrent glioblastoma; and CDX-011, an antibody-drug conjugate, which completed a randomized Phase IIb study for the treatment of advanced breast cancer.
To review Celldex’s stock, please take a look at the 1-year chart of CLDX (Celldex Therapeutics, Inc.) below with my added notations:
1-year chart of CLDX (Celldex Therapeutics, Inc.)
Over the last year CLDX has consistently moved higher. Since August the stock has formed a trendline of support (blue) that it has been bouncing on top of. Always remember that any (2) points can start a trendline, but it’s the 3rd test and beyond that confirm its importance. CLDX’s trendline seems to be very important now that it has been tested 5 times dating back to August.

The Tale of the Tape: CLDX has created a trendline of support over the last 7 months. A long position could be entered on a pullback to that trend line, which is currently sitting right around $23-24, with a stop placed below that level. A short position could be entered if CLDX were to break the trend line support.
Please share this article

Crude Headed to $80s? Massive Speculative Positions vs. It’s the Economy Stupid

With the slowdown in China, and global slowdown in general, inquiring minds may be wondering “where is the price of oil headed?”
No one can answer that question with certainty, but Saxo Bank has an opinion worth considering.
Via email Steen Jakobsen, chief economist of Saxo Bank explains …
 It’s not my role to run Saxo’s official view on Crude. That job I leave to my expert Ole S. Hansen, who by the way is doing an excellent job.
This is how we see the rest of 2014 using our data:
Oil in US Dollars
Please share this article

Martin Armstrong: Political Gambling & Next Major Market Collapse

Please share this article